

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR

<u>L25</u>	L24 and metformin	5	<u>L25</u>
<u>L24</u>	(baldness or balding or hirsutism).ti. or l23	1978	<u>L24</u>
<u>L23</u>	(baldness or balding or hirsutism).ab. or l22	1894	<u>L23</u>
<u>L22</u>	(baldness or balding or hirsutism).clm.	291	<u>L22</u>
<u>L21</u>	L20 and (biguanide or metformin)	7	<u>L21</u>
<u>L20</u>	alopecia.ab. or alopecia.ti. or alopecia.clm.	2908	<u>L20</u>
<u>L19</u>	alopecia.ab	0	<u>L19</u>
<u>L18</u>	L17 and (hair or alopecia or bald or balding or baldness)	0	<u>L18</u>
<u>L17</u>	l14 or l15	72	<u>L17</u>
<u>L16</u>	s l14 or l15L15	5796922	<u>L16</u>
<u>L15</u>	?\$dimethyldiguanide	2	<u>L15</u>
<u>L14</u>	?\$dimethylbiguanide	71	<u>L14</u>
<u>L13</u>	siofor	0	<u>L13</u>
<u>L12</u>	L8 and (hair or alopecia or bald or balding or baldness)	0	<u>L12</u>
<u>L11</u>	L8 and hirsutism	0	<u>L11</u>
<u>L10</u>	L8 same hair	0	<u>L10</u>
<u>L9</u>	L8 same (hair or alopecia or bald or balding or baldness)	0	<u>L9</u>
<u>L8</u>	(fluamine or flumamine or gliguanid or haurymelin or melbin or metiguanide)	66	<u>L8</u>
<u>L7</u>	metformin same (bald or balding)	0	<u>L7</u>
<u>L6</u>	\$4biguanide same (bald or balding)	0	<u>L6</u>
<u>L5</u>	\$4biguanide same (alopecia)	0	<u>L5</u>
<u>L4</u>	?\$biguanide same (hair or alopecia)	0	<u>L4</u>
<u>L3</u>	\$\$biguanide same (hair or alopecia)	16	<u>L3</u>
<u>L2</u>	?\$biguanide same (hair or alopecia)	0	<u>L2</u>
<u>L1</u>	?biguanide same hair	0	<u>L1</u>

END OF SEARCH HISTORY

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
L24 and metformin	5

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** Friday, August 15, 2003 [Printable Copy](#) [Create Case](#)

(FILE 'HOME' ENTERED AT 13:54:56 ON 15 AUG 2003)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIODBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 13:55:05 ON 15 AUG 2003

L1 40275 S METFORMIN OR ?BIGUANIDE
L2 44871 S METFORMIN OR ?BIGUANIDE?
L3 36939 S METFORMIN OR BIGUANIDE
L4 702 S L3 AND (HIRSUTI? OR HAIR)
L5 142 S L4 AND PD<2000
L6 131 DUP REM L5 (11 DUPLICATES REMOVED)
L7 101 S L6 AND (HAIR)
L8 2 S L7 AND (BALD?)
L9 0 S HYPERTRICHOSIS (P) METFORMIN
L10 2 S L7 AND ALOPECIA
L11 39 S HAIR (P) METFORMIN
L12 2 S L11 AND PD<2000

=>

=> d 12 1-3 bib,ab,kwic

L2 ANSWER 1 OF 3 CANCERLIT on STN DUPLICATE 1
AN 1999154857 CANCERLIT
DN 99154857 PubMed ID: 10037253
TI The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome.
AU Unluhizarci K; Kelestimur F; Sahin Y; Bayram F
CS Department of Endocrinology, Erciyes University School of Medicine, Kayseri, Turkey.
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY, (1999 Jan) 140 (1) 56-61.
Journal code: 9423848. ISSN: 0804-4643.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 1999154857
EM 199903
ED Entered STN: 19990428
Last Updated on STN: 19990428
AB OBJECTIVE: To determine whether **metformin**. when given to non-diabetic women with polycystic ovary syndrome (PCOS), results in a reduction of insulin resistance and hyperinsulinemia while body weight is maintained. Also we aimed to see whether the reduction in insulin levels attenuates the activity of adrenal P450c17alpha enzyme in patients with PCOS. DESIGN: We investigated the 17-hydroxyprogesterone (17-OHP) and androstenedione responses to ACTH, insulin responses to an oral glucose tolerance test (OGTT) and glucose disposal rate in an insulin tolerance test before and after **metformin** therapy (500 mg, orally, twice daily, for 12 weeks). METHODS: The presence of hyperinsulinemia in 15 women with PCOS was demonstrated by an OGTT and results were compared with those of 10 healthy women. Insulin sensitivity was measured by the rate of endogenous glucose disposal after i.v. bolus injection of insulin. 17-OHP and androstenedione responses to ACTH were measured in all the women with PCOS and the normal women. RESULTS: Women with PCOS were hyperinsulinemic (102.0+/-13.0 (S.E.M.) VS 46.2+/-4.4 pmol/l) and hyperandrogenemic (free testosterone 15.3+/-1.7 vs 7.9+/-0.6 nmol/l; androstenedione 11.8+/-0.8 vs 8.2+/-0.6 nmol/l) and more **hirsute** (modified Ferriman-Gallwey score, 17.7+/-1.6 vs 3.0+/-0.3) than healthy women. In addition, women with PCOS had higher 17-OHP and androstenedione responses to ACTH when compared with healthy women. **Metformin** therapy resulted in some improvement in insulin sensitivity and reduced the basal and post-glucose load insulin levels. But 17-OHP and androstenedione responses to ACTH were unaltered in response to **metformin**. CONCLUSIONS: PCOS is characterized by hyperactivity of the adrenal P450c17alpha enzyme and insulin resistance. It seems that there is no direct relationship between insulin resistance and adrenal P450c17alpha enzyme dysregulation.
AB OBJECTIVE: To determine whether **metformin**. when given to non-diabetic women with polycystic ovary syndrome (PCOS), results in a reduction of insulin resistance and hyperinsulinemia while. . . . responses to an oral glucose tolerance test (OGTT) and glucose disposal rate in an insulin tolerance test before and after **metformin** therapy (500 mg, orally, twice daily, for 12 weeks). METHODS: The presence of hyperinsulinemia in 15 women with PCOS was. . . . (102.0+/-13.0 (S.E.M.) VS 46.2+/-4.4 pmol/l) and hyperandrogenemic (free testosterone 15.3+/-1.7 vs 7.9+/-0.6 nmol/l; androstenedione 11.8+/-0.8 vs 8.2+/-0.6 nmol/l) and more **hirsute** (modified Ferriman-Gallwey score, 17.7+/-1.6 vs 3.0+/-0.3) than healthy women. In addition, women with PCOS had higher 17-OHP and androstenedione responses to ACTH when compared with healthy women. **Metformin** therapy resulted in some improvement in insulin sensitivity and reduced the basal and post-glucose load insulin levels. But 17-OHP and androstenedione responses to ACTH were unaltered in response to **metformin**. CONCLUSIONS: PCOS is characterized by

hyperactivity of the adrenal P450c17alpha enzyme and insulin resistance.
It seems that there is no. . .

FILE 'PHARMAML' ENTERED AT 14:52:39 ON 15 AUG 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIN' ENTERED AT 14:52:39 ON 15 AUG 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'TOXCENTER' ENTERED AT 14:52:39 ON 15 AUG 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPAT2' ENTERED AT 14:52:39 ON 15 AUG 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

28 FILES SEARCHED...

L1 17 (METFORMIN AND HIRSUTE) /TI,AB

L2 3 DUP REM L1 (14 DUPLICATES REMOVED)

(FILE 'HOME' ENTERED AT 14:52:32 ON 15 AUG 2003)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIODBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 14:52:39 ON 15 AUG 2003

L1 17 S (METFORMIN AND HIRSUTE)/TI,AB
L2 3 DUP REM L1 (14 DUPLICATES REMOVED)